ClinicaliQ Trial Snapshot
- Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus) — Active Not Recruiting • Phase II • Infectious Disease • NCT06497504.
- Bepirovirsen compared to placebo for treating people with both HIV and hepatitis B infection, measuring effectiveness and safety.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection. Conditions: Hepatitis B Interventions: Bepirovirsen, Placebo Lead Sponsor: GlaxoSmithKline Planned Enrollment: 153 participants